Pressure BioSciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

Schedule of Disaggregation of Revenue

In thousands of US dollars ($)	Three Months Ended June 30,				Six Months Ended June 30,
Primary geographical markets	2023		2022		2023		2022
North America	$	261	$	253	$	816	$	571
Europe		18		2		54		48
Asia		233		243		382		359
	$	512	$	498	$	1,252	$	978

	Three Months Ended June 30,				Six Months Ended June 30,
Major products/services lines	2023		2022		2023		2022
Hardware	$	293	$	247	$	721	$	531
Consumables		57		76		123		116
Contract research services		31		110		36		125
Sample preparation accessories		37		21		82		52
Technical support/extended service contracts		46		36		89		53

Agrochem Products		35		-		166		83
Shipping and handling		8		8		27		18
Other		5		-		8		-
	$	512	$	498	$	1,252	$	978

	Three Months Ended June 30,				Six Months Ended June 30,
Timing of revenue recognition	2023		2022		2023		2022
Products transferred at a point in time	$	435	$	352	$	1,127	$	800
Services transferred over time		77		146		125		178
	$	512	$	498	$	1,252	$	978

Schedule of Contract Balances

Contract balances

Schedule of Contract Balances

In thousands of US dollars ($)

June 30,

2023

December 31,

2022

Receivables, which are included in ‘Accounts Receivable’

189

295

Contract liabilities (deferred revenue)

Schedule of Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

In thousands of US dollars ($)		2023				2024				Total
Extended warranty service		$	58			$	6			$	64

Schedule of Customer Concentration Risk Percentage

The following table illustrates the level of concentration as a percentage of total revenues during the three and six months ended June 30, 2023 and 2022.

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Top five customers		70	%		69	%		55	%		61	%
Federal agencies		1	%		0	%		1	%		0	%

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.

	June 30, 2023			December 31, 2022
Top Five Customers		72	%		93	%
Federal Agencies		0	%		0	%

Schedule of Computation of Loss Per Share

The following table illustrates our computation of loss per share for the three and six months ended June 30, 2023 and 2022:

	2023			2022			2023			2022
	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2023			2022			2023			2022
Numerator:
Net loss attributable to common shareholders	$	(11,114,925	)	$	(3,348,046	)	$	(18,404,566	)	$	(8,019,880	)
Denominator for basic and diluted loss per share:
Weighted average common stock shares outstanding		19,471,057			10,462,520			17,629,225			10,029,068
Loss per common share - basic and diluted	$	(0.57	)	$	(0.32	)	$	(1.04	)	$	(0.80	)

Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share

	As of June 30,
	2023		2022
Stock options		3,420,754		1,307,822
Convertible debt		7,058,298		6,102,145
Common stock warrants		15,929,601		16,287,936
Convertible preferred stock:
Series D Convertible Preferred Stock		6,250		25,000
Series G Convertible Preferred Stock		-		26,857
Series H Convertible Preferred Stock		-		33,334
Series H2 Convertible Preferred Stock		-		70,000
Series J Convertible Preferred Stock		-		115,267
Series K Convertible Preferred Stock		-		229,334
Series AA Convertible Preferred Stock		8,601,000		8,645,000
Series BB Convertible Preferred Stock		3,620,000		-
Series CC Convertible Preferred Stock		4,010,000		-
		42,645,903		32,842,695

Summary of Assumptions for Grants of Stock Options

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the six months ended June 30, 2023:

Assumptions	CEO, other Officers and Employees
Expected life		6.0	(yrs)
Expected volatility		130.5	%
Risk-free interest rate		3.90	%
Forfeiture rate		0 to 5.00	%
Expected dividend yield		0.0	%

Schedule of Stock Based Compensation Expense

	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Cost of sales	$	11,060	$	2,161	$	64,541	$	6,510
Research and development		35,289		9,395		205,909		28,304
Selling and marketing		13,426		4,533		85,525		13,583
General and administrative		75,779		15,985		1,209,823		48,160
Total stock-based compensation expense	$	135,554	$	32,074	$	1,565,798	$	96,557

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2023:

			Fair value measurements at June 30, 2023 using:
	June 30, 2023		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Equity Securities	$	83,883	$	83,883		-		-
Total Financial Assets	$	83,883	$	83,883	$	-	$	-

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:

			Fair value measurements at December 31, 2022 using:
	December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Equity Securities		63,638		63,638		-		-
Total Financial Assets	$	63,638	$	63,638	$	-	$	-